2023
The impact of air pollution and endocrine disruptors on reproduction and assisted reproduction
Seli D, Taylor H. The impact of air pollution and endocrine disruptors on reproduction and assisted reproduction. Current Opinion In Obstetrics & Gynecology 2023, 35: 210-215. PMID: 36924404, DOI: 10.1097/gco.0000000000000868.Peer-Reviewed Original ResearchConceptsDiminished ovarian reserveOvarian reserveInfertility treatmentAbnormal semen parametersAssisted reproduction outcomesHuman reproductive healthEstrogen-like activityFemale reproductive functionEndocrine disruptorsPregnancy rateUterine leiomyomaReproductive healthReproduction outcomesReproductive functionSemen parametersClinical implicationsLarge-scale studiesAssisted reproductionSperm concentrationPatientsAir pollutionHealth impactsEndocrineTreatmentBisphenol A
2022
Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials
Donnez J, Taylor H, Stewart E, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland J, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E. Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials. Obstetrical & Gynecological Survey 2022, 77: 741-742. DOI: 10.1097/ogx.0000000000001113.Peer-Reviewed Original ResearchEndometriosis-associated infertility: From pathophysiology to tailored treatment
Bonavina G, Taylor H. Endometriosis-associated infertility: From pathophysiology to tailored treatment. Frontiers In Endocrinology 2022, 13: 1020827. PMID: 36387918, PMCID: PMC9643365, DOI: 10.3389/fendo.2022.1020827.Peer-Reviewed Original ResearchConceptsEndometriosis-associated infertilityRole of surgeryCurrent treatment optionsNon-invasive diagnostic toolLevel of impairmentInfertile womenRelated infertilityEndometrial receptivitySystemic diseaseTreatment optionsClinical managementDysfunctional alterationsEndometriosisSystemic effectsClinical situationsInfertilityPelvic anatomyClinical settingEndometriosis subtypesPrecise diagnosisPatient phenotypesReproductive technologiesDiagnostic toolTreatmentPhenotypeIncidence of Alopecia in Treatment of Women With Uterine Fibroids: Results of Two Phase 3 Trials of Linzagolix [A104]
Al-Hendy A, Taylor H, Catherino W, Stewart E, Bestel E, Garner E. Incidence of Alopecia in Treatment of Women With Uterine Fibroids: Results of Two Phase 3 Trials of Linzagolix [A104]. Obstetrics And Gynecology 2022, 139: 30s-30s. DOI: 10.1097/01.aog.0000826736.08037.1b.Peer-Reviewed Original ResearchPhase 3 trialUterine fibroidsGnRH antagonistHair lossPlacebo-controlled phase 3 trialUterine fibroid-related symptomsFibroid-related symptomsIncidence of alopeciaOral GnRH antagonistPooled safety analysisTreatment of womenConcomitant therapyTreatment discontinuationStudy drugWeek 52Mild alopeciaWeek 24Benign disorderSimilar incidenceLinzagolixSuppression dosesAlopeciaFibroidsTrialsTreatment